Group 1 - The core viewpoint of the article highlights that Shijiazhuang Pharmaceutical Group (01093.HK) reported a decline in its mid-year performance for 2025, with revenue and net profit both decreasing significantly [1] Group 2 - The company reported a revenue of 13.27 billion RMB for the first half of 2025, representing a year-on-year decrease of 18.5% [1] - The net profit for the same period was 2.55 billion RMB, which is a year-on-year decrease of 15.6% [1]

Group 1 - The core viewpoint of the article is that the company reported a significant decline in revenue and profit for the first half of 2025, primarily due to the inclusion of two products in centralized procurement [1] - The company's total revenue for the first half of 2025 was RMB 13.273 billion, representing an 18.5% year-on-year decrease [1] - The reported profit attributable to shareholders was RMB 2.548 billion, a decrease of 15.6% compared to the previous year [1] Group 2 - The basic earnings per share were RMB 0.2229, and the board declared an interim dividend of HKD 0.14 per share for the 2025 fiscal year [1] - The revenue from the prescription drug business was RMB 10.248 billion, down 24.4% year-on-year [1] - Revenue from raw material products increased by 11.9% to RMB 2.075 billion, while revenue from functional foods and other businesses grew by 8.0% to RMB 0.951 billion [1]

| 其他信息 | | --- | | 其他信息 不適用 | | 發行人董事 | | 於 本 公 告 日 期 ，董 事 會 包 括 執 行 董 事 蔡 東 晨 先 生 、張 翠 龍 先 生 、王 振 國 先 生 、潘 衛 東 先生、王懷玉先生、李春雷 博士、姚兵博士、蔡鑫先生及陳衛平先生；及獨立非執行董事王波先生、CHEN Chuan先生、王宏廣教授、歐振國先生、羅卓堅先 | | 生及李泉女士。 | 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 EF001 EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 石藥集團有限公司 | | 股份代號 | 01093 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年六月三十日止六個月之中期股息 | | ...

[Performance Summary](index=1&type=section&id=Performance%20Summary) [Financial Highlights](index=1&type=section&id=Financial%20Highlights) In H1 2025, the Group's total revenue decreased by 18.5% to RMB 13.273 billion, mainly due to a decline in the finished drug business, while profit attributable to shareholders decreased by 15.6% to RMB 2.548 billion H1 2025 Financial Highlights (RMB '000) | Indicator | H1 2025 | H1 2024 | Change | | :--- | :--- | :--- | :--- | | **Total Revenue** | **13,273,416** | **16,284,282** | **-18.5%** | | Finished Drug Revenue | 10,247,652 | 13,549,079 | -24.4% | | Raw Material Product Revenue | 2,074,708 | 1,854,794 | +11.9% | | Functional Food & Other Revenue | 951,056 | 880,409 | +8.0% | | **Profit Attributable to Shareholders** | **2,547,851** | **3,020,374** | **-15.6%** | | **Basic Profit Attributable to Shareholders** | **2,319,521** | **3,216,870** | **-27.9%** | | Basic EPS (RMB cents) | 22.29 | 25.51 | -12.6% | | Interim Dividend per Share (HK cents) | 14.00 | 16.00 | -12.5% | - The Board declared an interim dividend of **HKD 14 cents per share** for 2025, a decrease from **HKD 16 cents** in the prior year period[6](index=6&type=chunk) - The company repurchased and cancelled **64.3 million shares** for **HKD 300 million** in H1 2025 to enhance EPS and shareholder returns[6](index=6&type=chunk) [Company and Business Overview](index=2&type=section&id=Company%20and%20Business%20Overview) [Company Overview](index=2&type=section&id=Company%20Overview) CSPC Pharmaceutical Group is an innovation-driven, integrated pharmaceutical enterprise pursuing a 'innovation + internationalization' dual-engine strategy with a global R&D team and extensive pipeline - The Group adheres to a 'innovation + internationalization' dual-engine strategy, continuously increasing R&D investment and strengthening team building[7](index=7&type=chunk) - The Group has an international R&D team of over **2,000 people** across multiple global centers, focusing on six core therapeutic areas including oncology, neuropsychiatry, and cardiovascular[8](index=8&type=chunk) - The Group has completed **4 out-licensing projects** year-to-date, with cumulative contract value reaching **USD 9.71 billion**, and a strategic R&D collaboration with AstraZeneca on an AI platform[10](index=10&type=chunk) - The Group has over **200 innovative drugs and formulations** in development, with over **160 clinical trials** underway, and expects to file for market approval for over **50 new drugs or indications** by the end of 2028[11](index=11&type=chunk) [Finished Drug Business](index=4&type=section&id=Finished%20Drug%20Business) In H1 2025, finished drug revenue decreased by 24.4% to RMB 10.248 billion, primarily due to centralized procurement impacting core products, while out-licensing revenue provided new growth Finished Drug Business Revenue by Therapeutic Area (RMB '000) | Therapeutic Area | H1 2025 | H1 2024 | Change | | :--- | :--- | :--- | :--- | | Neuroscience | 3,754,814 | 5,235,700 | -28.3% | | Oncology | 1,050,606 | 2,683,139 | -60.8% | | Anti-infectives | 1,656,912 | 2,307,375 | -28.2% | | Cardiovascular | 868,336 | 1,228,902 | -29.3% | | Respiratory System | 575,441 | 756,025 | -23.9% | | Digestive & Metabolic | 528,099 | 646,697 | -18.3% | | Other | 738,777 | 691,241 | +6.9% | | **Subtotal Sales of Goods** | **9,172,985** | **13,549,079** | **-32.3%** | | Licensing Fee Income | 1,074,667 | – | Not Applicable | | **Total Revenue** | **10,247,652** | **13,549,079** | **-24.4%** | - Core products like Duomeisu and Jinyouli faced significant price adjustments due to centralized procurement policies, leading to temporary pressure on finished drug business revenue[13](index=13&type=chunk) - In H1 2025, the Group's licensing income reached **RMB 1.075 billion**, becoming a new growth driver for the finished drug business, with plans to develop it into a core source of recurring revenue[15](index=15&type=chunk) [Neuroscience](index=5&type=section&id=Neuroscience) Neuroscience sales declined due to price reductions for NBP® and Shuanling® from national centralized procurement, but Mingfule® saw significant growth after entering the medical insurance catalog - NBP® sales revenue decreased due to national medical insurance negotiation price reductions, but improved product accessibility[22](index=22&type=chunk) - Shuanling® injection was included in the 10th batch of national centralized procurement, leading to a significant decrease in sales revenue[22](index=22&type=chunk) - Mingfule® sales revenue significantly increased year-on-year in H1 due to its new indication entering the medical insurance catalog[22](index=22&type=chunk) [Oncology](index=6&type=section&id=Oncology) Oncology sales significantly declined due to Duomeisu® inclusion in national centralized procurement and Jinyouli®'s expanded centralized procurement, while new products provided growth - Duomeisu®'s inclusion in the 10th batch of national centralized procurement led to a substantial reduction in sales price, being the primary reason for the decline in this segment's revenue[29](index=29&type=chunk) - Jinyouli® sales revenue significantly decreased due to the expansion of the '3+N' alliance centralized drug procurement policy in Beijing-Tianjin-Hebei[29](index=29&type=chunk) - Duoenyi® sales revenue significantly increased year-on-year, and newly launched product Enshuxing® also provided new growth momentum for the business[29](index=29&type=chunk) [Anti-infectives](index=7&type=section&id=Anti-infectives) Anti-infectives business saw reduced sales for key products like Anfulike®, Weihong®, and Nuomoling® in H1 2025 due to weakened market demand, with only Shuluoke® showing growth - Sales revenue for products such as Anfulike®, Weihong®, and Nuomoling® all decreased due to weakened market demand[31](index=31&type=chunk) [Cardiovascular](index=8&type=section&id=Cardiovascular) Cardiovascular sales declined as Xuanning® was impacted by centralized procurement volume-based tasks in public medical institutions, while only Daxinning® achieved steady growth - Xuanning® sales in public medical institutions were affected by the implementation of volume-based tasks for centralized procurement products, leading to a year-on-year revenue decrease[36](index=36&type=chunk) [Respiratory System](index=9&type=section&id=Respiratory%20System) Respiratory system sales decreased overall, as market impacts on Qixin®, Nuoyian®, and Qixiao® offset stable growth from Yiluoda® and new contributions from Ennitan® - Yiluoda® sales revenue achieved steady growth, and new product Ennitan® contributed new growth points to this segment[40](index=40&type=chunk) - Sales revenue for products such as Qixin®, Nuoyian®, and Qixiao® all decreased due to market impact, leading to an overall revenue reduction in this segment[40](index=40&type=chunk) [Digestive & Metabolic](index=9&type=section&id=Digestive%20%26%20Metabolic) Digestive and metabolic sales declined overall, as competitive market conditions and a pricing strategy adjustment for Debixin® led to a decrease in average selling price - Debixin®'s sales strategy adjustment led to a decrease in its unit price, which was the main reason for the overall decline in sales revenue for this segment[43](index=43&type=chunk) [Raw Material Product Business](index=10&type=section&id=Raw%20Material%20Product%20Business) In H1 2025, raw material product sales increased by 11.9% to RMB 2.075 billion, driven by a 21.6% rise in Vitamin C revenue from strong overseas demand, while antibiotic sales remained flat Raw Material Product Business Revenue (RMB Billion) | Product Category | H1 2025 Revenue | Year-on-Year Growth | | :--- | :--- | :--- | | **Total** | **2.075** | **+11.9%** | | Vitamin C | 1.196 | +21.6% | | Antibiotics | 0.879 | Flat | - Vitamin C product revenue growth was primarily driven by significantly increased overseas market demand[46](index=46&type=chunk) [Functional Food and Other Businesses](index=11&type=section&id=Functional%20Food%20and%20Other%20Businesses) In H1 2025, functional food and other businesses generated RMB 951.056 million in sales revenue, an 8.0% increase, primarily due to higher caffeine sales volume - Functional food and other businesses revenue was **RMB 951.056 million**, a year-on-year increase of **8.0%**, mainly due to increased caffeine sales volume[48](index=48&type=chunk) [R&D Progress](index=11&type=section&id=R%26D%20Progress) [R&D Investment and Pipeline Overview](index=11&type=section&id=R%26D%20Investment%20and%20Pipeline%20Overview) In H1 2025, R&D expenses increased by 5.5% to RMB 2.683 billion, representing 26.2% of finished drug revenue, with nearly 90 products in clinical stages and 12 submitted for market approval R&D Expenses | Indicator | Amount (RMB) | Year-on-Year Change | % of Finished Drug Revenue | | :--- | :--- | :--- | :--- | | R&D Expenses | 2.683 billion | +5.5% | 26.2% | - Currently, nearly **90 products** are in different stages of clinical trials, with **12 submitted for market approval** and over **30 key products** in registration clinical stages[49](index=49&type=chunk) [Registration and Approval Progress](index=11&type=section&id=Registration%20and%20Approval%20Progress) Year-to-date, the Group achieved significant regulatory milestones in China with 3 innovative product approvals and 5 marketing application acceptances, alongside 9 IND approvals and 1 Fast Track designation in North America - Year-to-date, the Group obtained approval for **3 innovative products** in China, accepted **5 marketing applications**, and received **4 breakthrough therapy designations**[50](index=50&type=chunk) Products Approved for Marketing in H1 2025 | Month | Drug Name | Indication | | :--- | :--- | :--- | | January 2025 | Sanzeping® (Pluoglitin Tablets) | Improving glycemic control in adults with type 2 diabetes | | February 2025 | Ennitan® (Omalizumab for Injection) | Treatment of moderate to severe persistent allergic asthma | | June 2025 | Meiluotai® (Meloxicam Injection (III)) | Moderate to severe pain in adults | Products with Marketing Applications Accepted in H1 2025 | Month | Investigational Drug | Indication | | :--- | :--- | :--- | | March 2025 | Aprepitant Injection | Prevention of postoperative nausea and vomiting | | March 2025 | Irinotecan Liposome Injection | First-line metastatic pancreatic cancer | | March 2025 | Paliperidone Palmitate Injection (1M) | Schizophrenia | | June 2025 | Pregabalin Extended-Release Tablets | Diabetic peripheral neuropathic pain and postherpetic neuralgia | | August 2025 | Semaglutide Injection | Glycemic control in adults with type 2 diabetes | [Key Clinical Research Progress](index=14&type=section&id=Key%20Clinical%20Research%20Progress) During the period, the Group initiated or completed first patient enrollment for multiple pivotal clinical trials across oncology, depression, and hypertension, with key studies reaching top-line results and findings published in international conferences - First patient enrollment achieved for Phase III clinical trials of multiple drugs including JSKN003, Amcitine Hydrochloride Enteric-coated Tablets, and SYS6010[60](index=60&type=chunk)[61](index=61&type=chunk) - TG103 Injection (GLP-1) Phase III clinical trial for the treatment of overweight and obesity completed its clinical study report[64](index=64&type=chunk) - Semaglutide Injection Phase III clinical trial for the treatment of type 2 diabetes completed its clinical study report[66](index=66&type=chunk) - Multiple research findings were presented as oral reports or posters at international conferences such as AACR, ASCO, and ESMO, gaining international recognition[67](index=67&type=chunk)[68](index=68&type=chunk)[69](index=69&type=chunk) [Clinical Pipeline Overview](index=20&type=section&id=Clinical%20Pipeline%20Overview) The Group maintains a robust clinical pipeline with multiple products submitted for market approval in China and the US, alongside dozens of ongoing pivotal clinical trials utilizing advanced technologies - Submitted marketing applications for **10 drugs** in China, including Semaglutide Injection (for type 2 diabetes) and Irinotecan Liposome Injection (for first-line pancreatic cancer)[70](index=70&type=chunk) - Submitted marketing applications for **2 drugs** in the United States, namely Amphotericin B Liposome for Injection and Irinotecan Hydrochloride Liposome Injection[70](index=70&type=chunk) - Over **20 pivotal clinical trials** are ongoing in China, covering high-demand therapeutic areas such as breast cancer, gastric cancer, obesity, diabetes, and depression[71](index=71&type=chunk)[72](index=72&type=chunk)[73](index=73&type=chunk) [Business Development and Financial Review](index=24&type=section&id=Business%20Development%20and%20Financial%20Review) [Business Development](index=24&type=section&id=Business%20Development) In H1 2025, the Group achieved significant business development breakthroughs through out-licensing, completing four major agreements with substantial potential transaction values, including a strategic AI platform collaboration with AstraZeneca - Reached an exclusive licensing agreement with Radiance Biopharma for ADC drug SYS6005, with a potential total value of up to **USD 1.24 billion**[76](index=76&type=chunk) - Reached an exclusive licensing agreement with Cipla USA for the commercialization rights of Irinotecan Liposome Injection in the US, with a potential total value of up to **USD 1.065 billion**[77](index=77&type=chunk) - Reached a strategic R&D collaboration with AstraZeneca on an AI drug discovery platform, with a potential total value of up to **USD 5.33 billion**[78](index=78&type=chunk) - Reached a global exclusive licensing agreement with Madrigal Pharmaceuticals for small molecule GLP-1 agonist SYH2086, with a potential total value of up to **USD 2.075 billion**[79](index=79&type=chunk) [Financial Review](index=25&type=section&id=Financial%20Review) In H1 2025, revenue decreased by 18.5% and gross margin by 6 percentage points to 65.6% due to centralized procurement, while operating expenses significantly decreased, and R&D investment continued to grow, maintaining a robust financial position - Revenue decreased by **18.5%** to **RMB 13.273 billion**, and gross margin decreased by **6.0 percentage points** to **65.6%**, primarily due to the inclusion of Duomeisu® and Jinyouli® in centralized procurement and a reduced proportion of finished drug business revenue[80](index=80&type=chunk) - Sales and distribution expenses decreased by **36.2%** year-on-year to **RMB 3.049 billion**, mainly due to significantly lower sales expenses for products winning centralized procurement bids[83](index=83&type=chunk) - R&D expenses increased by **5.5%** year-on-year to **RMB 2.683 billion**, primarily for ongoing and newly initiated clinical studies[84](index=84&type=chunk) - Cash inflow from operating activities was **RMB 3.187 billion**, significantly higher than **RMB 1.425 billion** in the prior year period[88](index=88&type=chunk) - As of June 30, 2025, the Group's bank deposits, balances, and cash reached **RMB 10.291 billion**, with a debt-to-asset ratio of only **0.7%**, indicating a robust financial position[89](index=89&type=chunk) [Condensed Consolidated Financial Statements](index=28&type=section&id=Condensed%20Consolidated%20Financial%20Statements) [Condensed Consolidated Statement of Profit or Loss](index=28&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss) For the six months ended June 30, 2025, the Group reported revenue of RMB 13.273 billion, a 18.5% decrease, and profit for the period of RMB 2.574 billion, a 15.6% decrease, despite reduced operating expenses Condensed Consolidated Statement of Profit or Loss (RMB '000) | Item | H1 2025 | H1 2024 | | :--- | :--- | :--- | | Revenue | 13,273,416 | 16,284,282 | | Gross Profit | 8,710,192 | 11,654,547 | | Sales and Distribution Expenses | (3,049,160) | (4,777,410) | | R&D Expenses | (2,682,631) | (2,541,991) | | Profit Before Tax | 3,117,667 | 3,801,130 | | Profit for the Period | 2,574,050 | 3,051,466 | | Profit Attributable to Owners of the Company | 2,547,851 | 3,020,374 | [Condensed Consolidated Statement of Financial Position](index=30&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2025, total assets were RMB 46.002 billion, total liabilities RMB 11.138 billion, and net assets RMB 34.864 billion, all showing slight increases from year-end 2024, with improved net current assets Condensed Consolidated Statement of Financial Position Summary (RMB '000) | Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Total Assets** | **46,002,354** | **44,388,991** | | Non-current Assets | 23,392,266 | 22,500,847 | | Current Assets | 22,610,088 | 21,888,144 | | **Total Liabilities** | **11,138,478** | **10,522,701** | | Current Liabilities | 10,112,501 | 9,634,027 | | Non-current Liabilities | 1,025,977 | 888,674 | | **Net Assets/Total Equity** | **34,863,876** | **33,866,290** | [Other Information](index=40&type=section&id=Other%20Information) [Share Repurchase](index=40&type=section&id=Share%20Repurchase) As of June 30, 2025, the company repurchased and cancelled 64.3 million shares for approximately HKD 300 million, aiming to enhance earnings per share and shareholder value Share Repurchase Details | Month | Number of Shares Repurchased | Highest Price (HKD) | Lowest Price (HKD) | Total Consideration (HKD) | | :--- | :--- | :--- | :--- | :--- | | January | 38,850,000 | 4.72 | 4.38 | 176,597,000 | | March | 3,000,000 | 4.95 | 4.88 | 14,763,000 | | April | 22,450,000 | 4.95 | 4.66 | 108,155,000 | | **Total** | **64,300,000** | | | **299,515,000** |

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 74.71%, Green Power Environmental (01330) at 69.95%, and China Shenhua (01088) at 68.06% [1] - The largest increases in holdings over the last five trading days were seen in the following companies: Yingfu Fund (02800) with an increase of 134.21 billion, Hang Seng China Enterprises (02828) with an increase of 66.24 billion, and Southern Hang Seng Technology (03033) with an increase of 51.77 billion [1] - The largest decreases in holdings over the last five trading days were recorded for Anta Sports (02020) with a decrease of 10.21 billion, Geely Automobile (00175) with a decrease of 7.70 billion, and HSBC Holdings (00005) with a decrease of 7.40 billion [2] Group 1: Hong Kong Stock Connect Holding Ratios - China Telecom (00728) has a holding of 10.368 billion shares, representing 74.71% [1] - Green Power Environmental (01330) has a holding of 0.283 billion shares, representing 69.95% [1] - China Shenhua (01088) has a holding of 2.299 billion shares, representing 68.06% [1] Group 2: Recent Increases in Holdings - Yingfu Fund (02800) saw an increase of 134.21 billion in holdings, with a change of 52.386 million shares [1] - Hang Seng China Enterprises (02828) experienced an increase of 66.24 billion, with a change of 7.216 million shares [1] - Southern Hang Seng Technology (03033) had an increase of 51.77 billion, with a change of 95.870 million shares [1] Group 3: Recent Decreases in Holdings - Anta Sports (02020) had a decrease of 10.21 billion in holdings, with a change of -10.268 million shares [2] - Geely Automobile (00175) experienced a decrease of 7.70 billion, with a change of -38.819 million shares [2] - HSBC Holdings (00005) saw a decrease of 7.40 billion, with a change of -7.332 million shares [2]

Group 1 - The core point of the news is that Wantai Biological's nine-valent HPV vaccine has received approval for market release in China, making it the first domestically produced nine-valent HPV vaccine approved for sale in the country [1] - The approval is expected to enhance the company's product lineup, creating new revenue and profit growth opportunities, and strengthening its market position [1] - The nine-valent HPV vaccine will complement the existing bivalent HPV vaccine, forming a competitive product matrix to meet diverse consumer needs [1] Group 2 - The domestically produced nine-valent HPV vaccine utilizes a novel E. coli expression system, offering advantages such as good immunogenicity, rapid growth, short production cycles, high yield, low cost, and scalability [2] - Clinical studies show that the domestic nine-valent HPV vaccine has comparable immunogenicity and safety to imported versions, with a 100% seroconversion rate for all nine HPV types and similar adverse reaction rates [2] - The vaccine is priced at 499 yuan per dose, approximately 40% lower than imported nine-valent HPV vaccines, making it more accessible [2] Group 3 - The rapid development of domestic HPV vaccines is supported by national policies, including the "Cervical Cancer Elimination Action Plan (2023-2030)" aimed at promoting HPV vaccination [2] - There is significant potential for increasing the overall vaccination rate in the domestic population, as awareness of HPV vaccination is gradually improving [2] - Multiple domestic companies, including Bowe Biotechnology, Kangla Health, Ruike Biotechnology, and Watson Bio, are advancing their nine-valent HPV vaccine development, with several already in phase III clinical trials [3] Group 4 - The Chinese HPV vaccine market is projected to expand significantly, potentially reaching a scale of 62.54 billion yuan by 2031, driven by the completion of clinical trials and increased vaccination awareness [3] - New technological approaches, such as mRNA vaccines, are being explored for HPV vaccination, with several companies already in clinical stages of developing domestic mRNA HPV vaccines [3]

Group 1 - The article provides a ranking of the top 10 open-end funds based on net asset value growth as of August 21, 2025, highlighting the performance of various funds [2][4][7] - The top-performing fund is "汇添富双鑫添利债券D" with a net value of 1.2019, showing a significant increase from 1.0000 [2] - The bottom-performing fund is "前海开源周期精选混合C," which has a net value of 1.0343, down from 1.0816 [4][7] Group 2 - The article notes that a total of 28,402 funds have updated their net values, indicating a broad market activity [3] - The sectors leading the market include multi-financial and telecommunications, both showing gains of over 2% [7] - The article mentions that the "万家中证港股通创新药ETF" has experienced rapid net value growth, indicating strong performance in the healthcare sector [7] Group 3 - The article discusses the concentration of holdings in the top funds, with "万家中证港股通创新药ETF" having a concentration of 67.67% in its top ten holdings, primarily in the pharmaceutical sector [8] - The top holdings in this fund include "信达生物" and "药明生物," which have shown significant daily increases [8] - Conversely, the "前海开源周期精选混合C" fund has a lower concentration of 58.34% in its top holdings, with notable declines in some of its key stocks [8]

Group 1: Core Companies and Industries - Notable companies such as Huawei, DeepSeek, CATL, Zhongzhong Group, Alibaba, Tencent, and BYD are recognized in the 2025 Fortune China Technology 50 list, with a focus on popular sectors like artificial intelligence, robotics, biomedicine, and green energy [3][9][10] - The robotics sector is highlighted with companies like Yushu Technology, Yundong Technology, and Luoshi Robotics, which are innovating in areas such as motion control, high-performance joint motors, and autonomous inspection robots [5][6] Group 2: Artificial Intelligence Developments - DeepSeek has gained significant attention, ranking in the top 10 for global open-source model downloads, with 163 million monthly active users as of June 2025, leading the AI-generated content application market [7] - ByteDance is also recognized for its substantial investment in AI, with a projected capital expenditure of 80 billion yuan in 2024, surpassing the combined total of Baidu, Alibaba, and Tencent [7] - Drip Technology, a provider of enterprise-level AI application solutions, ranks first in the Chinese market for its general enterprise operational decision-making model [8] Group 3: Biomedicine and Green Energy Innovations - The biopharmaceutical sector features companies like CSPC Pharmaceutical Group, which is developing over 200 innovative drug projects across various therapeutic areas, with over 50 new drugs expected to be submitted for approval by the end of 2028 [11] - Kangfang Biotech is noted for its comprehensive drug development system, with over 50 innovative drug candidates, 24 of which are in clinical stages, making it one of China's leading antibody drug developers [11] - Trina Solar has initiated a 49.9MW solar-storage integration project in the UK, which will supply power to over 16,500 households and reduce carbon emissions by nearly 15,000 tons annually [11] Group 4: Overall Industry Trends - The companies listed in the Fortune China Technology 50 are focusing on practical applications of large models in vertical sectors like finance and healthcare, optimizing efficiency while advancing robotics for high-risk tasks [12] - The emphasis is also on developing cleaner and more efficient energy solutions, promoting a harmonious relationship between humanity and nature [12]

（来源：ETF炼金师） 近期，港股市场的创新药板块引发了投资者的广泛关注。特别是在恒生科技（互联网）ETF的前景下， 投资者对港股创新药的前景充满期待。在分析这一领域的动态时，需要明确投资的时间框架，是中长线 投资还是短线交易。 在中长线投资的视角下，港股的医药企业的中期财报和政策面表态显得尤为重要。近期，恒瑞医药的中 报显示出积极的现金流状况，尽管其股价在港股市场表现平平，但相较A股已存在10%的溢价。此外， 药明生物和药明合联等CXO企业的中报也亮眼，受到了外资投行的积极评价，这表明外资对当前市场 的价值认可与信心。 然而，并非所有企业的表现都如预期，率先披露的再鼎医药虽然减亏，但未能达到市场预期，导致其股 价在短期内受到打压。市场普遍处于中报观望期，龙头企业如信达、百济、石药和康方等将在未来几天 集中发布财报，投资者需保持警惕。 针对短线交易的策略，外资的态度和市场资金的共识是关键。港股医药板块的定价权主要掌握在外资手 中，外部环境的稳定与否将直接影响投资者的操作策略。如果外资对创新药板块失去兴趣，可能会带来 整体的抛压，但目前并没有明显迹象表明外资会撤离。 在技术面分析中，近期资金的流入情况显示出稳健 ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 12.00 [1][5]. Core Views - The company reported a revenue of HKD 6.1 billion in 1H25, reflecting a 1% year-over-year increase, and a 25% decrease in net profit to HKD 1.17 billion [1]. - The revenue from innovative and barrier products increased to 51% in 1H25, up from 36.1% in 1H24, indicating a positive trend in product performance [1]. - The nuclear medicine segment showed significant growth, with revenue reaching HKD 422 million, a 105.5% year-over-year increase, driven by the rapid uptake of Y90 microspheres [3]. - The company expects stable operational profit in 2H25 due to a low base effect and continued growth in the pharmaceutical technology and nuclear medicine sectors [1][2]. Summary by Sections Pharmaceutical Technology - The pharmaceutical technology segment achieved revenue of HKD 3.84 billion in 1H25, a 2.9% year-over-year increase, with respiratory and critical care products growing by 9.9% [2]. - The company anticipates stabilization in revenue for 2025, driven by unique product advantages and the gradual clearing of procurement impacts [2]. Nuclear Medicine - The nuclear medicine segment's revenue surged to HKD 422 million in 1H25, primarily due to the rapid market penetration of Y90 microspheres [3]. - The company has a robust pipeline with 27 nuclear medicine projects, focusing on integrated tumor diagnosis and treatment [3]. R&D Pipeline - The STC3141 project is expected to progress to Phase III trials within the year, with promising data from Phase II trials [4]. - The company is also looking to enhance its product portfolio through potential business development opportunities [4]. Profit Forecast and Valuation - The company forecasts net profits of HKD 2.1 billion, HKD 2.4 billion, and HKD 2.6 billion for 2025, 2026, and 2027 respectively [5]. - The target price of HKD 12.00 is based on a 20x PE ratio for 2025, aligning with comparable companies in the Hong Kong market [5].